Categories
Category: Company news
AI Drug Discovery Leaders Gain a Competitive Edge with Telesis Bio’s Gibson SOLA® Platform, Generating Development Candidates Faster
SAN DIEGO, Calif. — Telesis Bio® Inc., maker of the world’s only intelligent, on-premises DNA synthesis solution for AI labs, today announced recent commercial licensing agreements with several AI-native drug discovery companies. The agreements reflect a growing understanding that integrating…
Harnessing the Power of Synthetic Biology
Introducing the Next Generation Automated Synthetic Biology Workstation Telesis Bio recently announced the commercial release of the BioXp® 9600 system – a fully automated, high-throughput benchtop platform for synthetic biology workflows designed to empower scientists to accelerate discovery of new…
Telesis Bio and MBC Biolabs partner for discovery and automation of synthetic biology applications
We’re thrilled to announce the partnership with MBC Biolabs, a premier biotech incubator in the Bay Area. Under the terms of the collaboration, MBC Biolabs will leverage Telesis Bio’s BioXp® system to empower entrepreneurs in life sciences research with the…
Case study: How Cellibre transformed enzyme engineering with Telesis Bio
In San Diego, scientists at ag biotech startup Cellibre are looking to replace traditional agriculture for producing high-value ingredients. One of their first targets is the highly valuable cannabinoid market, which they believe can be disrupted by producing natural, high-quality,…
BioXp® system chosen as one of the year’s best innovations by The Scientist
There’s celebrating in the halls — and virtual halls — of Telesis Bio. We are truly honored that our new BioXp® 3250 system was selected as one of the year’s best innovations by The Scientist. This is a very prestigious…